Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The aim of this multicenter randomized phase II trial is to determine the efficacy of
sorafenib and irinotecan combination versus irinotecan monotherapy or versus sorafenib
monotherapy in metastatic colorectal cancer patients with KRAS mutated tumors after failure
of all active drugs known to be effective.